RxDoctor Payments Data

Jason Maxfield, MD

Sleep Medicine · Joplin, MONPI 1053572966

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (54.8%), food and beverage and education — rather than concentrated in one kind of arrangement. Inspire Medical Systems, Inc. accounts for 82.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $815 and has fallen 77.0% since, to $187 in 2025.

$1,917in general payments, 2019–2025

Across 25 payments — averaging $76.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$2K
  • Harmony Biosciences LLC$119
  • Resmed Corp$62
  • Jazz Pharmaceuticals Inc.$58
  • Fisher & Paykel Healthcare Inc$23
  • Lilly USA, LLC$19
  • plus $47 from 3 others

What the payments were for

  • Travel & lodging$1,05055%
  • Food & beverage$77240%
  • Education$955%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,917 in reported general payments places this provider in the 65th percentile of 33 sleep medicine providers in Missouri.

See all sleep medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$85,456
Medicare patients
512
Services billed
876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl18$290,128
BelsomraSuvorexant142$66,281
SunosiSolriamfetol Hcl32$30,976
DayvigoLemborexant43$19,355
QuviviqDaridorexant Hcl26$12,956
Armodafinil93$8,950
Pregabalin197$5,385
Pramipexole ErPramipexole Di-Hcl11$2,328
Doxepin Hcl42$2,260
Gabapentin131$1,204
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$931
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine23$823
Modafinil34$707
Eszopiclone16$564
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$119$290,12818 claims
Eisai Inc.Dayvigo$16$19,35543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 33 sleep medicine providers in Missouri.

Other sleep medicine in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →